NCT02781311Phase 2Completed
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males
In the register
The register attaches this trial to Setipiprant (AbbVie), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Allergan
- Participants (registry)
- 169
- Start
- July 2016
- Primary completion
- March 2018
- Study completion
- May 2018
- Last registry update
- April 2019
- Countries
- United States
Conditions studied: Alopecia
Interventions: Setipiprant, KYTH-105, AGN-241679, Placebo, Finasteride
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.